Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ROBYN R YOUNG

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1962452474
CMS profile
361254
Location
FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$9,022.98

134 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ROBYN R YOUNG

NPI 1962452474 · CMS profile ID 361254

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

FORT WORTH, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
ROBYN R YOUNG, NPI 1962452474, CMS profile ID 361254, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–134 of 134 matching records. This page contains 34 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1962452474?year=2024&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

134 matching records · $9,022.98 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 134 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–134 of 134.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $23.4504/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110777477 CMS
Merck Sharp & Dohme LLC $15.5504/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141750459 CMS
PUMA BIOTECHNOLOGY, INC. $124.4004/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113843818 CMS
AstraZeneca Pharmaceuticals LP $18.6603/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110545113 CMS
PUMA BIOTECHNOLOGY, INC. $12.8503/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1113851737 CMS
Novartis Pharmaceuticals Corporation $21.2703/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346738 CMS
E.R. Squibb & Sons, L.L.C. $13.1703/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101234755 CMS
Tactile Systems Technology Inc $21.1903/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1082372607 CMS
Novartis Pharmaceuticals Corporation $83.3303/15/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346760 CMS
Novartis Pharmaceuticals Corporation $20.4103/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346734 CMS
Lilly USA, LLC $13.6003/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135337913 CMS
SERVIER PHARMACEUTICALS LLC $24.8403/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147263135 CMS
Eisai Inc. $24.0903/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110777475 CMS
Takeda Pharmaceuticals U.S.A., Inc. $23.8603/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137701450 CMS
AstraZeneca Pharmaceuticals LP $30.9702/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110547732 CMS
AstraZeneca Pharmaceuticals LP $23.2902/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110538447 CMS
BeiGene USA, Inc. $26.4602/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120865020 CMS
Gilead Sciences, Inc. $111.3302/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133802886 CMS
Karyopharm Therapeutics Inc. $18.3802/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145536231 CMS
Novartis Pharmaceuticals Corporation $83.3302/16/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346758 CMS
Karyopharm Therapeutics Inc. $18.8802/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1145536227 CMS
Eisai Inc. $24.8002/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110777479 CMS
Incyte Corporation $21.2802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141287660 CMS
PharmaEssentia USA Corporation $32.8802/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137303128 CMS
Adaptive Biotechnologies Corporation $22.9902/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1150263555 CMS
Novartis Pharmaceuticals Corporation $20.3201/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346730 CMS
Daiichi Sankyo Inc. $24.8201/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089501050 CMS
AstraZeneca Pharmaceuticals LP $125.0001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110535068 CMS
Novartis Pharmaceuticals Corporation $24.9601/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346732 CMS
Novartis Pharmaceuticals Corporation $11.1301/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346728 CMS
Novartis Pharmaceuticals Corporation $83.3301/18/2024 Long term medical supply or device loan No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087346756 CMS
Stemline Therapeutics Inc. $21.4801/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142963582 CMS
Daiichi Sankyo Inc. $24.5301/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089501048 CMS
AstraZeneca Pharmaceuticals LP $30.9901/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1110545461 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $32,448.43 56
PY2020 $504.20 16
PY2021 $6,424.47 22
PY2022 $11,201.95 50
PY2023 $10,248.28 94
PY2024 $9,022.98 134
PY2025 $6,368.56 129

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $416,279.45 19
PY2024 Principal investigator $311,020.69 33
PY2023 Recipient $2,028.73 1
PY2023 Principal investigator $452,965.16 32
PY2022 Principal investigator $1,187,832.99 58
PY2021 Principal investigator $845,269.59 44
PY2020 Principal investigator $1,197,077.07 59
PY2019 Recipient $1,529.00 1
PY2019 Principal investigator $435,146.21 53

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $140,807.02 12/31/2025 Non-covered Recipient Entity
The Center for Cancer and Blood Disorders
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination with Pembrolizumab Versus Treatment of Physician s Choice in Participants with HR,HER2-Unresectable Locally Advanced or Metastatic Breast Cancer No dispute reported 06/30/2026 1232923136
Principal investigator 1 PFIZER INC. $3,525.00 11/17/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228728901
Principal investigator 1 PFIZER INC. $3,525.00 11/10/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228737489
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,500.00 11/05/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared with Investigators Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) No dispute reported 06/30/2026 1185542664
Principal investigator 1 PFIZER INC. $500.00 09/02/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228760175
Principal investigator 1 PFIZER INC. $350.00 08/25/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228767836
Principal investigator 1 Genentech, Inc. $535.00 08/20/2025 Non-covered Recipient Entity
CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211584745
Principal investigator 1 PFIZER INC. $312.32 08/11/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228767899
Principal investigator 1 AstraZeneca Pharmaceuticals LP $56,353.39 07/29/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
DESTINY-Breast07 will investigate the safety tolerability and anti-tumour activity of trastuzumab deruxtecan (T-DXd) in combination with other anti-cancer agents in patients with HER2-positive Metastatic Breast Cancer No dispute reported 06/30/2026 1185542658
Principal investigator 1 Eli Lilly and Company $20,036.00 06/10/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CONSULTANTS P A
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187888856
Principal investigator 1 Genentech, Inc. $2,535.94 06/09/2025 Non-covered Recipient Entity
CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA
Chemo trastuzumab vs chemo trastuzumab pertuzumab No dispute reported 06/30/2026 1211584730
Principal investigator 1 PFIZER INC. $624.64 04/14/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND
RANDOMIZED DOUBLEBLIND PHASE 3 STUDY OF TUCATINIB OR PLACEBO IN COMBINATION WITH ADOTRASTUZUMAB EMTANSINE TDM1 FOR SUBJECTS WITH UNRESECTABLE LOCALLYADVANCED OR METASTATIC HER2 BREAST CANCER HER2CLIMB02 No dispute reported 06/30/2026 1228779955
Principal investigator 1 Genentech, Inc. $5,371.00 04/08/2025 Non-covered Recipient Entity
CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA
A phase III trial of GDC 9545 in combination with palbo in HR HER2 neg 1L mBC No dispute reported 06/30/2026 1211584741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,728.13 02/28/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd followed by THP Compared to ddAC-THP in Participants with High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11) No dispute reported 06/30/2026 1185542662
Principal investigator 1 Genentech, Inc. $25,930.00 02/20/2025 Non-covered Recipient Entity
CENTER FOR CANCER + BLOOD DISORDERS ONCOLOGY HEMATOLOGY CONSULTANTS PA
Phase III study to compare inavolisib plus fulvestrant versus alpelisib plus fulvestrant in mBC No dispute reported 06/30/2026 1211584737
Principal investigator 1 Novartis Pharmaceuticals Corporation $17,665.68 02/14/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
Ribociclib Standard Endocrine therapy in patients with HR HER2 Early BC at High amp Intermediate Risk for Recurrence No dispute reported 06/30/2026 1190303559
Principal investigator 1 Eli Lilly and Company $1,512.10 02/10/2025 Non-covered Recipient Entity
ONCOLOGY HEMATOLOGY CONSULTANTS P A
EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+, HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE No dispute reported 06/30/2026 1187888472
Principal investigator 1 AstraZeneca Pharmaceuticals LP $51,904.13 01/15/2025 Non-covered Recipient Entity
THE ONEONCOLOGY RESEARCH NETWORK LLC
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd) Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (TROPION Breast04) No dispute reported 06/30/2026 1185542660
Principal investigator 1 AstraZeneca Pharmaceuticals LP $71,564.10 01/03/2025 Non-covered Recipient Entity
THE CENTER FOR CANCER AND BLOOD DISORDERS
A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan?(DatoDXd) With or Without Durvalumab Versus Investigators Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy No dispute reported 06/30/2026 1185542666